Skip to main content

Table 6 The association between chemotherapy regimen, relapse status, and WEnCA result in 88 stage III CRC patients

From: Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array

Chemotherapy regimen (N)

WEnCA (N)

Relapse

No relapse

P-value

 

N = 42 (%)

N = 46 (%)

 

FOLFOX-4 plus Cetuximab (N = 59)

Positive (N = 8)

6 (75)

2 (25)

0.047

 

Negative (N = 51)

17 (33.3)

34 (66.7)

 

FOLFOX-4 (N = 29)

Positive (N = 6)

3 (50)

3 (50)

0.633

 

Negative (N = 23)

16 (48.5)

7 (21.2)

Â